• Magazine
  • ENEWS
  • SUBSCRIBE
  • WEBINARS
  • PODCASTS
  • EBOOKS
  • Home

    • Editors' (re)View

    Welcome to Editors' (re)View, our editors’ weekly takes on things going on in the pharma world that deserve some extra consideration.

    Articles

    editreview

    Editor's (re)view: BIOSECURE Act hits legislative roadblock with passage in question

    The proposed legislation, which prevents U.S. federal funds from supporting certain Chinese contract manufacturers, was omitted from a defense bill leaving its fate in limbo.
    editreview

    Editor’s (re)view: Big Pharma doubles down on manufacturing investments

    This week, drug manufacturers — including Amgen, Eli Lilly, Novo Nordisk and Sanofi — announced plans to expand their production footprints in the U.S., Europe and Asia.

    Editors' (re)View: J&J's third bankruptcy bid faces DOJ pushback

    Pharma Manufacturing editors comment on the notable happenings in the pharma industry from the week of October 21

    Editors' (re)View: Warren asks FTC to step in on Novo, Catalent merger

    Pharma Manufacturing editors comment on the notable happenings in the pharma industry from the week of October 6

    Editors' (re)View: A new era of pharmacological innovation

    Pharma Manufacturing editors comment on the notable happenings in the pharma industry from the week of Sept 23

    Editors' (re)View: Granules India Limited hit with 483

    Pharma Manufacturing editors comment on the notable happenings in the pharma industry from the week of Sept 16

    Editors' (re)View: Lilly ventures into the dark genome; China's crackdown on pharma

    Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of Sept 2

    Editors' (re)View: Emergent secures mpox vax approval; The DTC push 

    Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of Aug 26.

    Editors' (re)View: Supply chains and espionage; Emergent sends mpox vaccines to Africa

    Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of Aug 19

    Editors' (re)View: Incyte stays busy; A generic IRA perspective

    Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of Aug 11

    Editors' (re)View: Roche takes a chance on genomics; Weight loss drugs beyond obesity treatment

    Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of Aug 5

    Editors' (re)View: The fate of Lykos’ MDMA treatment; Pfizer gives up on DMD gene therapy

    Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of July 28

    Editors' (re)View: FDA’s rare disease push; Strides in Batten disease treatment

    Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of July 21

    Editors' (re)View: Greetings from Portugal; The future of weight loss drugs

    Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of July 14

    Editors' (re)View: FDA second chances; FTC takes aim at PBMs

    Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of July 8